Skip to main content

Table 3 Secondary endpoints

From: Asthma rehabilitation at high vs. low altitude: randomized parallel-group trial

 Low altitudeHigh altitudeBetween group difference of changes from BL to 3 weeksBetween group difference of changes from BL to 3 months
 BaselineEnd of rehabilitation
(3 weeks)
Follow-up
(3 months)
BaselineEnd of rehabilitation
(3 weeks)
Follow-up
(3 months)
FEV1, %pred.61 (42;77)96 (54;80)*71 (58;83)*64 (59;71)78 (67;83)***72 (58;85)*3.6 (−4.9 to 10.9)1.7 (-7.3 to 9.6)
FVC, %pred.83 (63;93)87 (79;96)*87 (77;94)82 (74;92)91 (83;98)**84 (78;95)1.5 (−5.5 to 10.2)−.45 (-7.0 to 6.1)
FEV1/ FVC, pre.63 (.52;.69).63 (.53;.70).67 (.54;.70)*.67 (.59;.71).70 (.63;.75)***.69 (.6;.75)**.01 (−.03 to .05).01 (−.04 to .06)
6MWD, m490 (452;510)521 (493;549)***504 (486;536)*536 (491;571)571 (522;624)**570 (517;607)−2 (-24 to 22)4 (-26 to 31)
STS, repetitions21 (19;24)24 (21;26)**25 (22;28)**25 (23;28)36 (30;40)***30 (27;39)***7 (4 to 11)4 (0 to 7)
FeNO, ppb37 (25;58)19 (36;51)51 (35;76)27 (23;52)**−18 (−36 to 0) 
Hemoglobin, g/l139 (131;150)139 (125;145) 142 (127;158)145 (138;166) 7 (4 to 11) 
EOS, 10^9/l.39 (.28;.63).31 (.18;.57) .38 (.28;.57).26 (.18;.45) −.05 (−.16 to .04) 
EOS, %6.3 (5.0;9.3)5.4 (2.7;7.1)*6.2 (5.1;8.6)3.9 (2.4;6.5)***−1.1 (−2.6 to 0.5) 
  1. Note: Data are given as median (quartiles) and median difference (confidence interval)
  2. Abbreviations: FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, 6MWD 6 min walking distance, STS Sit-to-stand, FeNO exhaled nitric oxid, EOS blood eosinophils
  3. *: p < 0.05; **: p < 0.01; ***: p < 0.001 tested with Wilcoxon test for paired samples (baseline vs. 3 week follow up and baseline vs. 3 months follow up); bold: significant between group differences
\